PARIBLIEVA 150 mg contains Olaparib, an oral PARP (Poly ADP-ribose polymerase) inhibitor. It blocks DNA repair in cancer cells, especially those with BRCA1/BRCA2 mutations, leading to accumulation of DNA damage and selective cancer cell death (synthetic lethality).

Uses (Indications)

Olaparib is indicated for:

1. Ovarian Cancer
     – BRCA-mutated (germline or somatic), recurrent or maintenance therapy

2. Breast Cancer
     – HER2-negative, BRCA-mutated metastatic breast cancer

3. Pancreatic Cancer
     – Metastatic, BRCA-mutated (maintenance therapy)

4. Prostate Cancer
     – Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations

Common side effects:

•   Nausea, vomiting

•   Fatigue, weakness

•   Anemia

•   Loss of appetite

•   Diarrhea

Hematological side effects:

•   Anemia

•   Neutropenia

•   Thrombocytopenia

Serious side effects:

•   Myelodysplastic syndrome (MDS) / Acute myeloid leukemia (rare)

•   Pneumonitis (rare)

Regular CBC monitoring is essential.

Dosage

Dosage depends on indication and patient tolerance.

Standard adult dose:

   •   300 mg twice daily (total 600 mg/day)

150 mg tablets are used to make the recommended dose
(e.g., 2 tablets twice daily).


NOTE: This medicine should be taken only under a doctor’s supervision.